Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors

AJ Syder, H Lee, MB Zeisel, J Grove, E Soulier, J Macdonald, S Chow, J Chang, TF Baumert, Jane McKeating, J McKelvy, F Wong-Staal

Research output: Contribution to journalArticlepeer-review

109 Citations (Scopus)


BACKGROUND AND AIMS: ITX 5061 is a clinical stage small molecule compound that promotes high-density lipoprotein (HDL) levels in animals and patients by targeting the scavenger receptor BI protein pathway. Since SR-BI is a known co-receptor for HCV infection, we evaluated these compounds for their effects on HCV entry. METHODS: We obtained ITX 5061 and related compounds to characterize their interaction with SR-BI and effects on HCV entry and infection. RESULTS: We confirmed that a tritium-labeled compound analog (ITX 7650) binds cells expressing SR-BI, and both ITX 5061 and ITX 7650 compete for HDL-mediated lipid transfer in an SR-BI dependent manner. Both molecules inhibit HCVcc and HCVpp infection of primary human hepatocytes and/or human hepatoma cell lines and have minimal effects on HCV RNA replication. Kinetic studies suggest that the compounds act at an early post-binding step. CONCLUSIONS: These results suggest that the ITX compounds inhibit HCV infection with a mechanism of action distinct from other HCV therapies under development. Since ITX 5061 has already been evaluated in over 280 patients with good pharmacokinetic and safety profiles, it warrants proof-of-concept clinical studies in HCV infected patients.
Original languageEnglish
Pages (from-to)48-55
Number of pages8
JournalJournal of Hepatology
Issue number1
Publication statusPublished - 1 Jan 2011


  • SR-BI antagonists
  • HCV entry inhibitors


Dive into the research topics of 'Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors'. Together they form a unique fingerprint.

Cite this